When a pharmaceutical company is creating a compound that could become the next wonder drug, it helps to have a clean slate on which to build the drug. That?s the concept behind Scarab Genomics, 1202 Ann St., a company that grew out of research at the UW-Madison laboratories of genetics professor Fred Blattner, the company?s president and chief executive officer.
Office of Strategic Communication